Research Topics
| David R StaskinSummaryAffiliation: Cornell University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Methodologic shortcomings inherent in a post-hoc analysisDavid R Staskin
New York Presbyterian Hospital, Weill-Cornell Medical School, New York, NY 10021, USA
Curr Urol Rep 3:431-3. 2002- Overactive bladder in the elderly: a guide to pharmacological managementDavid R Staskin
Department of Urology, Weill Cornell Medical School, New York Presbyterian Hospital, New York, NY 10021, USA
Drugs Aging 22:1013-28. 2005..The pharmacology and clinical effects of current medication for the treatment of OAB symptoms in patients defined by the OAB pharmacology literature as 'elderly' are also reviewed... - Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditionsD R Staskin
Weill Medical College of Cornell University, New York, NY 10021, USA
Int J Clin Pract 62:27-38. 2008..We present a subanalysis of results from men with OAB in a 6-month, open-label study of treatment with the oxybutynin transdermal system (OXY-TDS). Broad entry criteria were incorporated to yield a clinically representative population... - Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trialDavid Staskin
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York 10021, USA
J Urol 178:978-83; discussion 983-4. 2007..An extended release formulation of trospium chloride was recently developed for the once daily treatment of overactive bladder. We investigated the safety, efficacy and tolerability of 60 mg trospium chloride once daily... - Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladderDavid R Staskin
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th Street F9 West, New York, NY 10021, USA
Urol Clin North Am 33:465-73, viii. 2006..The low incidence of adverse event of central nervous system effects and the efficacy parameters of "urgency" and "onset of action" are highlighted... - Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinenceDavid R Staskin
Female Urology and Voiding Dysfunction, Weill Medical College of Cornell University, New York, NY 10021 USA
BJU Int 97:1256-61. 2006.... - Pharmacologic management of overactive bladder: practical options for the primary care physicianDavid R Staskin
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA
Am J Med 119:24-8. 2006..Patient-initiated control of OAB symptoms may be achieved in 1 month by following established protocols... - Using anticholinergics to treat overactive bladder: the issue of treatment tolerabilityDavid R Staskin
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA
Am J Med 119:9-15. 2006..Recent dose-adjustment data with extended-release oxybutynin suggest that, given some control in the process, patients are willing to tolerate certain side effects in exchange for symptom relief... - Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladderDavid R Staskin
Department of Urology, Weil Cornell Medical College, New York, NY 10021, USA
Curr Urol Rep 5:423-6. 2004..Furthermore, there was no difference in these findings across age groups... - The urge to define urgency: a review of three approachesDavid R Staskin
Weill-Cornell Medical College, 525 East 68th Street, F 918, New York, NY 10021, USA
Curr Urol Rep 5:413-5. 2004 - Future studies of overactive bladder: the need for standardizationDavid R Staskin
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical School, New York, New York, USA
Urology 60:90-3. 2002..However, a subtler, but possibly more critical problem exists: the method of defining the population and the methods for collecting the data for the efficacy outcome parameters, including frequency, urgency, and urge incontinence... - Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 gramsDoreen E Chung
Weill Cornell Medical College, Cornell University, New York, New York 10065, USA
Urology 75:1144-8. 2010..TER is indicated for OAB and DUT is indicated for LUTS from benign prostatic hyperplasia... - Extended-release trospium chloride improves quality of life in overactive bladderRoger R Dmochowski
Department of Urology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Value Health 13:251-7. 2010..The pooled health-related QoL (HRQoL) data from two multicenter, parallel-group, double-blind Phase III studies with trospium chloride ER 60 mg were analyzed... - Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional studyRoger R Dmochowski
Department of Urology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Urology 71:449-54. 2008..This randomized controlled trial evaluated the efficacy and tolerability of this new extended-release formulation, trospium chloride 60 mg QD... - Overview consensus statementDavid R Staskin
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA
Urology 60:1-6. 2002 - Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladderRoger R Dmochowski
Department of Urology, Vanderbilt University Medical Center, Room A 1302, Medical Center North, Nashville, TN 37232, USA
Urology 75:62-8. 2010..To evaluate the efficacy and tolerability of flexible-dose fesoterodine vs placebo in subjects with overactive bladder (OAB)... - Urinary retention and post-void residual urine in men: separating truth from traditionSteven A Kaplan
Department of Urology, Weill Medical College, Cornell University, New York, New York 10021, USA
J Urol 180:47-54. 2008.... - Transdermal delivery of drugs for urologic applications: basic principles and applicationsVictor W Nitti
New York University School of Medicine, New York, New York 10016, USA
Urology 67:657-64. 2006 - Artificial graft slings at the midurethra: physiology of continenceJennifer Tash
Section of Voiding Dysfunction, New York Presbyterian, Weill Cornell Medical College, 525 East 63rd Street F-918, New York, NY 10021, USA
Curr Urol Rep 4:367-70. 2003..Sommerville, NJ) procedure and the SPARC Sling System (American Medical Systems, Minneapolis, MN). They are used in this article to illustrate important clinical concepts... - Trospium chloride: a quaternary amine with unique pharmacologic propertiesRaymond W Pak
Department of Urology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
Curr Urol Rep 4:436-40. 2003..Some of the characteristics of this unique anticholinergic agent are reviewed in this article and the relative contributions of these factors are discussed... - Mixed incontinence: the misclassification of patients and limitations of clinical trialsRenuka Tyagi
Department of Urology, New York Presbyterian Hospitals, Weill Medical College of Cornell University, 525 East 68th Street, Suite F 9 West, New York, NY 10021, USA
Curr Urol Rep 6:424-8. 2005..Investigation into the pathophysiologic basis of MUI and refinement of the definition of MUI are necessary if we are to evaluate the effect of future treatments on stress and urge components... - Nocturia: when is it not related to overactive bladder?Konstantin Walmsley
Department of Urology, Weill Cornell Medical Center, New York Presbyterian Hospital, 525 East 68th Street, New York, NY 10021, USA
Curr Urol Rep 4:441-5. 2003..This article reviews the different nonurologic causes of nocturia. It also discusses the diagnostic algorithms necessary to identify specific factors underlying a patient's symptoms... - Solifenacin versus tolterodine--a head-to-head study: finally! But not final?David R Staskin
Curr Urol Rep 6:403-4. 2005 - Advances in drug delivery: improved bioavailability and drug effectRoger R Dmochowski
Department of Urologic Surgery, Vanderbilt University Medical Center, Medical Center North, Room A1302, Nashville, TN 37232, USA
Curr Urol Rep 3:439-44. 2002..These salubrious effects are, in part, due to the more stable serum-drug concentrations that are imparted by this long-acting formulation... - Autologous and synthetic urethral slings for female incontinenceKathleen Niknejad
Division of Urology, Brigham and Women's Hospital, Harvard Medical School, 45 Francis Street, Boston, MA 02115, USA
Urol Clin North Am 29:597-611. 2002..In the next decade, it is hoped that a better understanding of the factors that influence surgical success will translate into continued refinement of surgical technique... - Antimuscarinic therapy in men with bladder outlet obstructionDavid R Staskin
Curr Urol Rep 7:437-9. 2006 - Stimulating aspects of sacral nerve stimulationDavid R Staskin
J Urol 175:1991-2. 2006 - Is it possible to make cross-study comparisons of urinary continence rates in patients with overactive bladder?David R Staskin
Curr Med Res Opin 21:835-7. 2005..Here we propose ways in which logical adjustments can be made to account for differences in disease severity and placebo effects when considering continence data to allow estimation of relative effectiveness across studies... - Management of incontinence for family practice physiciansJohn P Lavelle
Division of Urologic Surgery, University of North Carolina School of Medicine, Urology Clinic UNC Hospital, Chapel Hill, North Carolina 27599, USA
Am J Med 119:37-40. 2006..Accurate diagnosis can lead to effective treatment when physicians are familiar with available treatment options, including pharmacologic, surgical, behavioral therapies, and catheterization... - The Q-T interval and antimuscarinic drugsRoger Dmochowski
Vanderbilt Continence Center, Vanderbilt University Medical Center, A 1302 Medical Center North, Nashville, TN 37232 2765, USA
Curr Urol Rep 6:405-9. 2005..The recently approved agents (trospium, solifenacin, darifenacin) used for the treatment of overactive bladder have been rigorously evaluated for these effects... - A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trialsAnnabel Nixon
Quintiles Strategic Research Services, Torrance, California 94107, USA
J Urol 174:604-7. 2005..We report the measurement properties of the IUSS...